The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk
Author:
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s00296-020-04616-2.pdf
Reference98 articles.
1. Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36:182–188. https://doi.org/10.1016/j.semarthrit.2006.08.006
2. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4:130–136. https://doi.org/10.1016/j.autrev.2004.09.002
3. Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL et al (2013) Rheumatoid arthritis and cardiovascular disease. Am Heart J166:622–628. https://doi.org/10.1016/j.ahj.2013.07.010
4. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71:1524–1529. https://doi.org/10.1136/annrheumdis-2011-200726
5. Chuang YW, Yu MC, Lin CL, Yu TM, Shu KH, Huang ST, Kao CH (2016) Risk of peripheral arterial occlusive disease in patients with rheumatoid arthritis. A nationwide population-based cohort study. Thromb Haemost 115:439–445. https://doi.org/10.1160/TH15-07-0600
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-07-25
2. Treating Cardiovascular Disease in the Inflammatory Setting of Rheumatoid Arthritis: An Ongoing Challenge;Biomedicines;2024-07-19
3. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment;Annals of the Rheumatic Diseases;2024-07-02
4. Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis;European Journal of Internal Medicine;2024-07
5. A Review of MicroRNAs and lncRNAs in Atherosclerosis as Well as Some Major Inflammatory Conditions Affecting Atherosclerosis;Biomedicines;2024-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3